Fintel reports that on May 10, 2024, Baird initiated coverage of Soleno Therapeutics (NasdaqCM:SLNO) with a Outperform recommendation. Analyst Price Forecast Suggests 47.74% Upside As of May 8 ...

SLNO stock is trading at a margin of 7.51%, 5.40% and 48.52% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices. 3 Tiny Stocks Primed to Explode The world's greatest investor — ...

Investors might want to bet on Soleno Therapeutics, Inc. (NASDAQ:SLNO), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- ...

Soleno Therapeutics shares are trading higher after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi Syndrome.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...

“Soleno’s top priority remains NDA submission for DCCR in PWS,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. “Receiving Breakthrough Therapy Designation from the FDA for ...

The firm increased its portfolio allocation in SLNO by 97.25% over the last quarter. Perceptive Advisors holds 3,075K shares representing 8.44% ownership of the company. No change in the last quarter.

Buy SLNO slightly over 41.27 target 50.61 stop loss @ 41.15 Details The technical summary data tells us to buy SLNO near 41.27 with an upside target of 50.61. This data also tells us to set a stop ...

(RTTNews) - Soleno Therapeutics Inc. (SLNO) said that it has priced underwritten public offering of 3 million shares of its common stock at $46.00 per share. SLNO closed Thursday's regular trading ...